Vertex Pharmaceuticals Inc/ US92532F1003 /
| 2024-05-08 10:00:00 PM | Chg. +8.5800 | Volume | Bid1:58:40 AM | Ask1:58:40 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 418.8200USD | +2.09% | 1.65 mill. Turnover: 398.47 mill. |
411.0000Bid Size: 100 | 418.9000Ask Size: 100 | 108.08 bill.USD | - | 29.81 |
Assets
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 789.4370 | 812.0050 | 758.0850 | 958.5340 | 1,094.1000 | ||||||
| Intangible Assets | 29 | - | 400 | 400 | 400 | ||||||
| Long-Term Investments | 20.4470 | - | - | - | - | ||||||
| Fixed Assets | 897.0510 | 2,402.7890 | 3,495.6360 | 3,618.4290 | 3,871.9000 | ||||||
| Inventories | 111.8300 | 124.3600 | 167.5020 | 280.7770 | 353.1000 | ||||||
| Accounts Receivable | 281.3430 | 409.6880 | 633.5180 | 885.3520 | 1,136.8000 | ||||||
| Cash and Cash Equivalents | 1,665.4120 | 2,650.1340 | 3,109.3220 | 5,988.1870 | 6,795 | ||||||
| Current Assets | 2,648.9630 | 3,843.1090 | 4,822.8290 | 8,133.3790 | 9,560.6000 | ||||||
| Total Assets | 3,546.0140 | 6,245.8980 | 8,318.4650 | 11,751.8080 | 13,432.5000 | ||||||
Liabilities
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 73.9940 | 110.9870 | 87.6100 | 155.1390 | 195 | ||||||
| Long-term debt | 583.9020 | 581.5500 | 538.5760 | 539.0420 | 509.8000 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | 6.3000 | - | - | - | - | ||||||
| Liabilities | 1,503.7080 | 1,810.6950 | 2,233.2210 | 3,064.9930 | 3,332.5000 | ||||||
| Share Capital | 2.5120 | 2.5460 | 2.5890 | 2.5990 | 2.5000 | ||||||
| Total Equity | 2,042.3060 | 4,435.2030 | 6,085.2440 | 8,686.8150 | 10,100 | ||||||
| Minority Interests | 13.7270 | 0.0000 | 0.0000 | 0.0000 | - | ||||||
| Total liabilities equity | 3,546.0140 | 6,245.8980 | 8,318.4650 | 11,751.8080 | 13,432.5000 | ||||||
Income Statement
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 2,488.6520 | 3,047.5970 | 4,162.8210 | 6,205.6830 | 7,574.4000 | ||||||
| Depreciation (total) | 61.3970 | 72.4200 | 106.9410 | 109.5150 | 125.6000 | ||||||
| Operating Result | 123.2430 | 635.1500 | 1,197.5660 | 2,856.2900 | 2,782.1000 | ||||||
| Interest Income | 57.5500 | 34.1190 | - | - | 61.5000 | ||||||
| Income Before Taxes | -15.6890 | 600.2410 | 1,394.9190 | 3,116.7980 | 2,730.4000 | ||||||
| Income Taxes | -107.3240 | -1,486.8620 | 218.1090 | 405.1510 | 388.3000 | ||||||
| Minority Interests Profit | 171.8490 | 9.7930 | 0.0000 | 0.0000 | - | ||||||
| Net Income | 263.4840 | 2,096.8960 | 1,176.8100 | 2,711.6470 | 2,342.1000 | ||||||
Per Share
Cash Flow
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 844.9420 | 1,270.2860 | 1,569.3300 | 3,253.5050 | 2,643.5000 | ||||||
| Cash Flow from Investing Activities | -437.6810 | -202.1580 | -1,235.3180 | 99.3880 | -340.9000 | ||||||
| Cash Flow from Financing | 68.4040 | -71.2190 | 126.7730 | -505.2810 | -1,478 | ||||||
| Decrease / Increase in Cash | 481.4670 | 990.7270 | 462.4280 | 2,868.1640 | 811.2000 | ||||||
| Employees | 2,300 | 2,500 | 3,000 | 3,400 | 3,900 | ||||||
